| Literature DB >> 21376412 |
Carolyn W Taylor1, Dorthe Brønnum, Sarah C Darby, Giovanna Gagliardi, Per Hall, Maj-Britt Jensen, Paul McGale, Andrew Nisbet, Marianne Ewertz.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2011 PMID: 21376412 PMCID: PMC3168733 DOI: 10.1016/j.radonc.2011.01.020
Source DB: PubMed Journal: Radiother Oncol ISSN: 0167-8140 Impact factor: 6.280
Estimated cardiac doses from common breast cancer radiotherapy regimens used to irradiate the breast, chest wall and internal mammary nodes in Denmark from 1977 to 2001.
| Description | Usual given or target dose (Gy) | Usual dose per fraction (Gy) | Field arrangement | Usual beam energy | Number women | Heart | LAD | RCA | Circ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean dose (Gy) | Mean BED (Gy2) | Mean dose (Gy) | Mean BED (Gy2) | Mean dose (Gy) | Mean dose (Gy) | ||||||||||||
| Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | ||||||
| Lateral thorax (and supraclavicular fossa) field (a) | 45.0 | 3.75 | Oblique anterior | 8–18 MV | 173 | 3.0 | 1.9 | 4.5 | 2.7 | 9.0 | 0.8 | 14.9 | 0.9 | 2.9 | 5.4 | 1.5 | 0.5 |
| Electron field to chest wall and internal mammary chain | 40.7 | 3.39 | Direct anterior | 10 MeV | |||||||||||||
| Wide tangential pair to chest wall (b) | 40.7 | 1.85 | Wide tangential pair | 6 MV | 58 | 8.5 | 2.7 | 14.9 | 3.8 | 23.5 | 1.6 | 45.7 | 2.0 | 3.3 | 11.0 | 3.6 | 1.0 |
| McWhirter (c) | 23.6–36.0 | 1.80 | Wide tangential pair | 250–300 keV | 46 | 14 | 9 | 25 | 13 | 43 | 5 | – | – | 10 | 19 | 7 | 4 |
| Lateral thorax (and supraclavicular fossa) field (a) | 45.0 | 3.75 | Oblique anterior | 4 MV | 22 | 4 | 2 | 5 | 3 | 6 | 1 | – | – | 2 | 2 | 2 | 1 |
| Orthovoltage scar boost (d) | 36.0 | 3.00 | Direct anterior | 100 keV | |||||||||||||
| Lateral thorax (and supraclavicular fossa) field (e) | 50.0–55.0 | 2.00–2.20 | Oblique anterior | 4–10 MV | 114 | 4.5 | 3.0 | 6.0 | 3.9 | 12.8 | 1.1 | 18.1 | 1.2 | 5.3 | 8.9 | 2.0 | 0.7 |
| Electron field to internal mammary chain | 54.0 | 2.16 | Direct anterior | 9–14 MeV | |||||||||||||
| Electron field to chest wall | 50.0 | 2.00 | Direct anterior | 6–10 MeV | |||||||||||||
| Tangential pair to breast (midline) (f) | 50.0 | 2.00 | Tangential pair | 6–10 MV | 6 | 6.0 | 1.7 | 9.2 | 1.9 | 23.5 | 1.4 | 41.6 | 1.7 | 2.2 | 3.2 | 3.0 | 1.1 |
| Tangential pair to breast (midline) (f) | 48.0 | 2.00 | Tangential pair | 6–10 MV | 132 | 6.1 | 1.7 | 11.9 | 1.9 | 24.0 | 1.4 | 58.5 | 1.5 | 2.1 | 3.3 | 3.0 | 1.1 |
| Electron scar boost (g) | 10.8 | 2.16 | Direct oblique | 8–15 MeV | |||||||||||||
| Tangential pair to breast (midline) (f) | 48.0 | 2.00 | Tangential pair | 6–10 MV | 59 | 6.3 | 1.8 | 12.4 | 1.9 | 24.8 | 1.5 | 62.8 | 1.6 | 2.3 | 3.4 | 3.0 | 1.1 |
| Tangential scar boost (h) | 10.0 | 2.00 | Tangential pair | 6–25 MV | |||||||||||||
| Oblique electron field to breast/chest wall (i) | 51.9 | 2.16 | Oblique anterior | 8–15 MeV | 27 | 4.7 | 2.1 | 7.2 | 2.6 | 17.6 | 0.6 | 35.2 | 0.6 | 2.7 | 6.4 | 2.0 | 0.6 |
| Electron scar boost (g) | 10.8 | 2.16 | Direct oblique | 8–18 MeV | |||||||||||||
| Oblique electron field to breast/chest wall (i) | 51.9 | 2.16 | Oblique anterior | 8–15 MeV | 15 | 4.4 | 2.0 | 6.0 | 2.5 | 16.2 | 0.6 | 26.1 | 0.9 | 2.6 | 6.2 | 1.9 | 0.6 |
| Wide tangential pair to breast/chest wall (b) | 48.0 | 2.00 | Wide tangential pair | 6–18 MV | 10 | 10.3 | 3.3 | 18.1 | 4.2 | 29.1 | 1.9 | 59.9 | 1.7 | 3.9 | 13.2 | 4.3 | 1.2 |
| Electron scar boost (g) | 10.8 | 2.16 | Direct oblique | 6–18 MeV | |||||||||||||
Estimates based on typical tumour dose and calculated on a representative patient with typical anatomy.
Each regimen presented was received by ⩾5 of the 681 women included in the study. Nineteen of the 681 women received other, less commonly used, regimens.
Given dose, i.e., dose at Dmax (maximum dose) where different from prescribed dose.
For some regimens, cardiac doses differed slightly from those of the patients described in Fig. 2 since tumour dose varied slightly from patient to patient.
BED (biologically effective dose) calculated using the linear quadratic equation: BED = [nd(1 + d/(α/β)] where n is number of fractions and d is dose per fraction in Gy. α/β was assumed to be 2. BEDs were based on average doses in first 300 women in the study except for wide tangential pair/electron scar boost and McWhirter regimens where there was more than 5 Gy difference between tumour doses for the first 300 women and final 681 women. LAD coronary artery BEDs are not presented for manually planned techniques since they are based on few dose points.
Left anterior descending coronary artery.
Right coronary artery.
Circumflex coronary artery.
New protocols were introduced in these years.
(a), (b) etc. refers to the illustrations in Fig. 1.
Regimen comprises both techniques, i.e., lateral thorax and chest wall & internal mammary chain.
Doses for manually planned regimens are rounded due to the uncertainties involved in planning. All other doses are given to 1 decimal place.
Fig. 1Danish breast cancer radiotherapy techniques reconstructed for cardiac dose estimations, ordered according to time period of irradiation.
Fig. 2Estimated mean heart (panel a) and left anterior descending coronary artery (LAD) (panel b) doses in Danish breast cancer patients irradiated between 1977 and 2001. Dose for the left-sided patients is represented by black bars and dose for the right-sided patients, by grey bars. Estimates are based on individual patient doses. Regimens were reconstructed on a typical patient with average anatomy.
Cardiac dose estimates for Danish women identified using the Danish Breast Cancer Group database and irradiated for breast cancer since 1977, based on individual radiotherapy charts.
| Year of radiotherapy | Number of women evaluated | Average mean dose (standard deviation) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Target dose (Gy) | Heart dose (Gy) | Heart BED | LAD | RCA | Circ | |||||||
| Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | |||
| 1977–1981 | 199 | 40.6 | 6.1 | 2.9 | 10.2 | 4.6 | 16.4 | 1.5 | 4.2 | 7.7 | 3.1 | 1.1 |
| (6.3) | (3.3) | (1.6) | (7.9) | (3.7) | (9.7) | (1.2) | (1.9) | (4.0) | (1.4) | (0.9) | ||
| 1982–1988 | 187 | 48.4 | 5.7 | 2.9 | 8.4 | 3.9 | 16.3 | 1.4 | 4.2 | 8.2 | 2.8 | 0.9 |
| (6.6) | (2.3) | (1.1) | (5.9) | (2.5) | (7.2) | (0.8) | (1.5) | (3.3) | (1.0) | (0.6) | ||
| 1989–2001 | 295 | 53.8 | 5.8 | 2.1 | 10.1 | 2.4 | 20.9 | 1.3 | 3.0 | 5.3 | 2.8 | 0.9 |
| (5.1) | (1.2) | (0.5) | (3.2) | (0.8) | (5.3) | (0.3) | (1.3) | (2.8) | (0.6) | (0.2) | ||
Regimens were reconstructed on a representative patient with typical anatomy.
Women were grouped according to the years that breast cancer protocols changed in Denmark. The DBCG77 protocol was mainly used between 1977 and 1981; the DBCG82 protocol between 1982 and 1988 and the DBCG89 protocol between 1989 and 2001.
The biologically effective dose (BED) takes into account the fraction size as well as dose and is given by BED = [nd(1 + d/(α/β)] where n is number of fractions and d is dose per fraction in Gy. α/β was assumed to be 2 Gray. It was possible to calculate BEDs for 97% of the women studied. It was not possible to calculate BED for the other 3% women who received unusual techniques such as iridium wire radiotherapy.
Left anterior descending coronary artery.
Right coronary artery.
Circumflex coronary artery.
Target dose includes boost radiotherapy.
Cardiac dose estimates for Swedish women identified using the Swedish nationwide cancer register and irradiated for breast cancer since 1977, based on individual radiotherapy charts.
| Year of radiotherapy | Number of women evaluated | Average mean dose (standard deviation) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Target dose (Gy) | Heart dose (Gy) | Heart BED | LAD | RCA | Circ | |||||||
| Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | |||
| 1977–1981 | 36 | 38.7 | 12.0 | 3.6 | 20.8 | 4.5 | 23.6 | 1.5 | 8.7 | 9.5 | 7.7 | 0.8 |
| (10.2) | (5.2) | (3.0) | (10.0) | (4.0) | (7.6) | (0.8) | (5.4) | (9.1) | (3.4) | (0.3) | ||
| 1982–1988 | 51 | 44.6 | 8.0 | 3.7 | 11.6 | 5.1 | 21.1 | 1.9 | 6.9 | 11.1 | 4.2 | 0.9 |
| (8.8) | (5.8) | (2.4) | (10.2) | (3.9) | (9.0) | (1.0) | (7.1) | (9.9) | (2.9) | (0.4) | ||
| 1989–2001 | 43 | 46.6 | 7.3 | 3.2 | 10.5 | 4.2 | 18.8 | 2.1 | 5.7 | 8.4 | 3.9 | 1.3 |
| (8.5) | (7.2) | (2.2) | (11.2) | (3.2) | (11.7) | (0.7) | (6.2) | (9.5) | (3.3) | (0.3) | ||
Regimens were reconstructed on a representative patient with typical anatomy.
Women were grouped according to the years that breast cancer protocols changed in Denmark to enable comparison with Danish women in Table 2.
The biologically effective dose (BED) takes into account the fraction size as well as dose and is given by BED = [nd(1 + d/(α/β)] where n is number of fractions and d is dose per fraction in Gy. α/β was assumed to be 2 Gray. It was possible to calculate BEDs for women who received computer planned technique combinations or a single manually planned technique (91% of the women studied). It was not possible to calculate BED for the other women who received two techniques, one of which was manually planned (9% of the women studied).
Left anterior descending coronary artery.
Right coronary artery.
Circumflex coronary artery.